Fatty Liver Clinical Trial
Official title:
Pilot Study for the Prediction of Donor Liver Adipose Content by Magnetic Resonance Imaging
Verified date | January 2018 |
Source | Vanderbilt University Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
A pilot prospective cohort study assessing the clinical utility of MRI evaluation of graft steatosis prior to transplantation will be conducted. An MRI of the donor liver within the transport cooler will be obtained on its way to the operating room.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | December 2018 |
Est. primary completion date | December 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 19 Years and older |
Eligibility |
Inclusion Criteria: - Patients who are scheduled to orthoptic liver transplant Exclusion Criteria: - Patient's who do not agree to sign consent |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Vanderbilt University Medical Center |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percent Hepatic Steatosis of a Donor Liver Prior to Transplantation | Amount of fat measured in the donor liver prior to transplant surgery using MRI scan | Measured immediately prior to liver transplant | |
Secondary | Comparison of steatosis percentages provided by biopsy to MRI results | Baseline | ||
Secondary | Length of hospitalization of transplant recipient | Days to hospital discharge, approximately 2 weeks | ||
Secondary | Mortality of liver transplant recipient at 1 year post transplantation | 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05979779 -
Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis
|
Phase 2 | |
Recruiting |
NCT06051669 -
Comparison of iLivTouch and FibroScan for the Assessment of Liver Fibrosis and Steatosis in Adult Patients in the US
|
||
Not yet recruiting |
NCT05984745 -
Effect of CoQ10 on the Outcome of MAFLD Patients
|
Phase 2 | |
Completed |
NCT02565446 -
Transforming Non-Invasive Liver Disease Detection by MRE: The Hepatogram
|
N/A | |
Not yet recruiting |
NCT01694342 -
Telomere Parameters in Patients With Nonalcoholic Fatty Liver
|
N/A | |
Completed |
NCT01464801 -
Resveratrol in Patients With Non-alcoholic Fatty Liver Disease
|
N/A | |
Completed |
NCT01992809 -
Omega 3 Supplementation in Fatty Liver
|
Phase 3 | |
Completed |
NCT00063635 -
Treatment of Nonalcoholic Fatty Liver Disease in Children (TONIC)
|
Phase 3 | |
Completed |
NCT00244569 -
Development of a Breath Test for Monitoring Patients With Liver Disease
|
Phase 3 | |
Recruiting |
NCT03972319 -
Omega-3 Supplementation for LIver VolumE Reduction Study (OLIVER) Study
|
Early Phase 1 | |
Completed |
NCT03141008 -
Evaluation of Liver and Cardiometabolic Health Benefits on Low Carbohydrate Ketogenic Diet
|
||
Completed |
NCT03614039 -
Effect of Probiotic and Smectite Gel on NAFLD
|
N/A | |
Recruiting |
NCT05125757 -
Lifestyle Modification in Psoriatic Patients With Fatty Liver
|
N/A | |
Recruiting |
NCT05370053 -
The Availability of the Enhanced Liver Fibrosis (ELF) Test Affects the Rate of Diagnosis of Nonalcoholic Steatohepatitis (NASH) With Fibrosis in Patients Referred to Hepatology
|
N/A | |
Recruiting |
NCT04371042 -
PROtocol of Metabolic and Cryptogenic livEr Disease regisTry for intEgration of Omic Studies
|
||
Completed |
NCT04004273 -
Diabetes, Exercise and Liver Fat (DELIVER)
|
N/A | |
Completed |
NCT02520609 -
Dynamic Post-Prandial Metabolism in Patients With Non-Alcoholic Fatty Liver Disease
|
||
Recruiting |
NCT02265276 -
A Prospective, Randomized Trial to Compare saroGLitazar With pioglitAZone in Nonalcoholic Fatty livEr Disease
|
Phase 3 | |
Completed |
NCT02347007 -
Impact of Almond Supplementation on Body Composition in Overweight/Obese Minority Adults
|
N/A | |
Completed |
NCT01934777 -
Efficacy and Tolerance of Treatment With DHA, Choline and Vitamin E in Children With Non-alcoholic Steatohepatitis
|
Phase 3 |